Compounds > indazoles
Page last updated: 2024-08-21

indazoles and dabrafenib

indazoles has been researched along with dabrafenib in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (90.91)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Nissan, MH; Rosen, N; Solit, DB1
Buijsman, RC; de Man, J; de Roos, JA; de Vetter, JR; Prinsen, MB; Spijkers-Hagelstein, JA; Uitdehaag, JC; van Doornmalen, AM; Zaman, GJ1
Bertino, E; Haglund, K; Haraldsdottir, S; Kaffenberger, B; Shah, MH1
Booth, L; Dent, P; Kirkwood, JM; Lee, J; Poklepovic, A; Roberts, JL; Sander, C1
Fulda, S1
Buclin, T; Cagnon, L; Cardoso, E; Csajka, C; Decosterd, L; Diezi, M; Ellefsen-Lavoie, K; Homicsko, K; Mercier, T; Michielin, O; Wagner, AD; Widmer, N1
Brown, B; Molloy, MP; Neilson, KA; Semaan, C1
Chen, H; Cheng, J; Duan, J; Geng, G; He, H; Hua, R; Jiang, X; Li, Q; Li, X; Li, Y; Liu, D; Wu, L; Xu, D; Yang, L1
Creixell, P; Jeschke, GR; Kim, J; Linding, R; Longden, J; Poulikakos, PI; Rosen, N; Santini, CC; Schoof, EM; Simpson, CD; Turk, BE; Wu, X1
Berger, MF; Cocco, E; Cownie, J; de Stanchina, E; Drilon, A; Ebata, K; Guzman, S; Hechtman, JF; Houck-Loomis, B; Hyman, DM; Kulick, A; Ladanyi, M; Lanman, RB; Mattar, M; Misale, S; Nagy, RJ; Patel, JA; Ptashkin, R; Razavi, P; Samoila, A; Scaltriti, M; Schram, AM; Selçuklu, SD; Shifman, S; Somwar, R; Toska, E; Tuch, BB; Won, HH; Yaeger, R1
E Schweppe, R; Espinoza, VL; Hicks, HM; LaBarbera, D; McKenna, LR; Pike, LA; Pozdeyev, N; Raeburn, CD; Reigan, P; Sams, SB1

Reviews

1 review(s) available for indazoles and dabrafenib

ArticleYear
Repurposing anticancer drugs for targeting necroptosis.
    Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Drug Repositioning; Humans; Imidazoles; Indazoles; Necrosis; Oximes; Pyridazines; Pyrimidines; Reperfusion Injury; Sorafenib; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib

2018

Trials

1 trial(s) available for indazoles and dabrafenib

ArticleYear
Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy.
    JAMA dermatology, 2016, 05-01, Volume: 152, Issue:5

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diagnosis, Differential; Femoral Neoplasms; Fracture Fixation, Intramedullary; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Oximes; Pyrimidines; Radiodermatitis; Radiotherapy, Adjuvant; Sulfonamides

2016

Other Studies

9 other study(ies) available for indazoles and dabrafenib

ArticleYear
ERK pathway inhibitors: how low should we go?
    Cancer discovery, 2013, Volume: 3, Issue:7

    Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Neoplasms; Oximes; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib

2013
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aza Compounds; Benzimidazoles; beta Catenin; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Oxazoles; Oximes; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Quinolines; Sulfonamides; Triazoles; Vemurafenib

2015
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
    Oncotarget, 2017, Mar-07, Volume: 8, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Male; Melanoma; Mice, Nude; Microscopy, Fluorescence; Oximes; Phenylbutyrates; Pyridones; Pyrimidines; Pyrimidinones; RNA Interference; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays

2017
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2018, Apr-15, Volume: 1083

    Topics: Administration, Oral; Antineoplastic Agents; Azetidines; Child; Chromatography, High Pressure Liquid; Humans; Imidazoles; Indazoles; Indoles; Limit of Detection; Linear Models; Oximes; Phenylurea Compounds; Piperidines; Pyridines; Pyridones; Pyrimidines; Pyrimidinones; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry; Vemurafenib

2018
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
    Anticancer research, 2018, Volume: 38, Issue:11

    Topics: Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Mutation; Naphthyridines; Oximes; Phenazines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Sulfonamides

2018
Raf-ERK1/2 signalling pathways mediate steroid hormone synthesis in bovine ovarian granulosa cells.
    Reproduction in domestic animals = Zuchthygiene, 2019, Volume: 54, Issue:5

    Topics: Animals; Cattle; Cells, Cultured; Estradiol; Female; Gene Expression; Granulosa Cells; Imidazoles; Indazoles; MAP Kinase Signaling System; Oximes; Piperazines; Progesterone; RNA, Messenger; Testosterone

2019
Global view of the RAF-MEK-ERK module and its immediate downstream effectors.
    Scientific reports, 2019, 07-26, Volume: 9, Issue:1

    Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Oximes; Phosphorylation; Piperazines; Proteome; Proteomics; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms

2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
    Nature medicine, 2019, Volume: 25, Issue:9

    Topics: Adolescent; Adult; Animals; Benzamides; Cell Proliferation; Cell-Free Nucleic Acids; Child; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Heterografts; Humans; Imidazoles; Indazoles; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Neoplasms; Oncogene Proteins, Fusion; Oximes; Protein Kinase Inhibitors; Pyrazoles; Pyridones; Pyrimidines; Pyrimidinones; Receptor, trkA; Young Adult

2019
Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.
    Molecular carcinogenesis, 2021, Volume: 60, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Oximes; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Thyroid Neoplasms; Xenograft Model Antitumor Assays

2021